Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Pediatr Neurol. 2014 Aug 7;51(5):607–618. doi: 10.1016/j.pediatrneurol.2014.08.002

Figure 7.

Figure 7

MHC class I staining of sarcolemmal membrane of muscle sections on treated (T) and control (C) sides. (A) Gene transfer leads to antigen presentation at the sarcolemma. The absence of MHC I in Subject 6 of the LGMD2D study was in direct contrast to the findings of all other participants in the clinical trial, illustrated by prominent MHC I expression shown in Subject 5 on the treated side. Blood vessels will show non-specific positive staining for MHC Igene . (B) Subject 6 of the LGMD2D gene transfer study also had an immune response demonstrated in the IFN-γ ELISpot assay to AAV1 capsid pool 2 (AAV1 CP2). This was seen as early as day 2 (Blue), and again on day 7. Responses were negative for other capsid pools (AAV1 CP1 and AAV1 CP3). The positive IFN-γ ELISpot assay occurring shortly after gene transfer was indicative of an amnestic response suggesting pre-existing immunity to AAV1.